Chromocell Therapeutics (Chromocell Therapeutics) Total Stockholders Equity : $1.13 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Total Stockholders Equity?

Chromocell Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $1.13 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Chromocell Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $0.20. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Chromocell Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Chromocell Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Chromocell Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Total Stockholders Equity Chart

Chromocell Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

-3.58

-3.68

-3.71

-6.45

Chromocell Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial							-4.40	-4.90	-5.91	-6.45	1.13

Chromocell Therapeutics (AMEX:CHRO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Chromocell Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1.13	-	0)	/	5.7667
	=	0.20

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Chromocell Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	1.13
	=	0.00

Chromocell Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.